Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -108.93% is 58% below its 5-year average of -68.97%, near the low end of its 5-year range (-128.23%–-31.89%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.78% below its 12-month average of -104.96%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -108.93%.
RETURN ON EQUITY (ROE)
-108.93%
RETURN ON EQUITY (ROE) AVG TTM
-104.96%
RETURN ON EQUITY (ROE) AVG 3Y
-74.99%
RETURN ON EQUITY (ROE) AVG 5Y
-68.97%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-3.78%
CURRENT VS 3Y AVG
-45.26%
CURRENT VS 5Y AVG
-57.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.35%
median of 344 covered companies
CURRENT VS SECTOR MEDIAN
-247.39%
vs the sector median at left
Annexon, Inc.
Market Cap
$688.14M
Return on Equity (ROE)
-108.93%
TTM Avg
-104.96%
3Y Avg
-74.99%
5Y Avg
-68.97%
Market Cap
$698.60M
Return on Equity (ROE)
-113.05%
TTM Avg
-95.98%
3Y Avg
-72.88%
5Y Avg
-73.85%
Market Cap
$675.41M
Return on Equity (ROE)
-43.95%
TTM Avg
-29.61%
3Y Avg
-34.61%
5Y Avg
-30.48%
Market Cap
$709.33M
Return on Equity (ROE)
15.36%
TTM Avg
25.54%
3Y Avg
15.72%
5Y Avg
18.75%
Market Cap
$719.64M
Return on Equity (ROE)
N/A
TTM Avg
-222.26%
3Y Avg
276.12%
5Y Avg
157.82%
Market Cap
$643.37M
Return on Equity (ROE)
-41.56%
TTM Avg
-67.38%
3Y Avg
-49.66%
5Y Avg
-56.07%
Market Cap
$642.31M
Return on Equity (ROE)
-21.51%
TTM Avg
-20.05%
3Y Avg
-35.91%
5Y Avg
-26.18%
Market Cap
$734.10M
Return on Equity (ROE)
-41.20%
TTM Avg
50554.28%
3Y Avg
25132.94%
5Y Avg
16622.35%
Market Cap
$637.59M
Return on Equity (ROE)
-8.42%
TTM Avg
-4.61%
3Y Avg
-3.17%
5Y Avg
11.46%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | $688.14M | -108.93% | -104.96% | -74.99% | -68.97% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | -113.05% | -95.98% | -72.88% | -73.85% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | -43.95% | -29.61% | -34.61% | -30.48% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 15.36% | 25.54% | 15.72% | 18.75% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | N/A | -222.26% | 276.12% | 157.82% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | -41.56% | -67.38% | -49.66% | -56.07% |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -21.51% | -20.05% | -35.91% | -26.18% |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -41.20% | 50554.28% | 25132.94% | 16622.35% |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | -8.42% | -4.61% | -3.17% | 11.46% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | -24.06% | -36.09% | -34.99% | -44.03% |
ROE
-108.9%
ROA
-82.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -108.93% |
| 2026-03-31 | -96.06% |
| 2025-12-31 | -97.66% |
| 2025-09-30 | -128.23% |
| 2025-06-30 | -93.92% |
| 2025-03-31 | -68.66% |
| 2024-12-31 | -47.15% |
| 2024-09-30 | -35.44% |
| 2024-06-30 | -31.89% |
| 2024-03-31 | -46.01% |
| 2023-12-31 | -53.58% |
| 2023-09-30 | -89.73% |
| 2023-06-30 | -77.58% |
| 2023-03-31 | -67.60% |
| 2022-12-31 | -61.40% |
| 2022-09-30 | -55.62% |
| 2022-06-30 | -86.57% |
| 2022-03-31 | -69.60% |
| 2021-12-31 | -56.20% |
| 2021-09-30 | -43.91% |
| 2021-06-30 | -32.57% |
| 2021-03-31 | -23.99% |
| 2020-12-31 | -18.42% |
| 2020-09-30 | -13.45% |
| 2020-06-30 | -37.30% |
| 2020-03-31 | -128.36% |
| 2019-12-31 | -85.42% |
| 2019-09-30 | -63.53% |
| 2019-06-30 | -130.33% |
| 2019-03-31 | -59.05% |
| 2018-12-31 | -48.79% |
